Biotech Values

[xavierprivas]

ZS-9 is the only drug without any interaction. Both Veltassa (RLYP)
and the old drug Kayexalate (sodium polystyrene sulfonate) have the
12 hour window mandated by the FDA. RLYP Veltassa and Kayexalate
will have negligible market share. There is nothing else on the market
approved for this indication.

http://www.fda.gov/Drugs/DrugSafety/ucm468035.htm

Time to short. Morgan Stanley analyst Berens has a price target for
RLYP of $9